MRRS adds "Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women.

There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies. The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Table of Contents
3 Marketed Products 24
3.1 Overview 24
3.1.1 Herceptin (trastuzumab) - Genentech 24
3.1.2 Perjeta (pertuzumab) - Genentech 26
3.1.3 Afinitor (everolimus) - Novartis 27
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis 28
3.1.5 Ibrance (palbociclib) - Pfizer 29
3.1.6 Ixempra (ixabepilone) - Bristol-Myers Squibb 29
3.1.7 Halaven (eribulin mesylate) - Eisai 30
3.1.8 Avastin (bevacizumab) - Genentech 31
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech 31
3.2 Marketed Products Heatmap 32
3.2.1 Herceptin 33
3.2.2 Perjeta 35
3.2.3 Afinitor 35
3.2.4 Tykerb/Tyverb 35
3.2.5 Ibrance 36
3.2.6 Ixempra 37
3.2.7 Halaven 37
3.3 Measuring the Effectiveness of Treatment 38
3.4 Conclusion 38
4 Pipeline Products 39
4.1 Overall Pipeline 39
4.1.1 Pipeline by Molecular Target 40
4.2 Clinical Trials 43
4.2.1 Failure Rate 43
4.2.2 Patient Enrollment and Clinical Trial Size 45
4.2.3 Duration 49
4.3 Competitive Clinical Trials Metrics Analysis 52
5 Promising Drug Candidates in Pipeline 53
5.1 Abemaciclib - Eli Lily 53
5.1.1 Abemaciclib Forecast 53
5.2 Buparlisib - Novartis 54
5.2.1 Buparlisib Forecast 55
5.3 Lynparza (olaparib) - AstraZeneca 56......

List of Tables and Figures 
Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013 16
Table 2: Breast Cancer Therapeutics Market, Global, Pipeline Products, Discovery, 2015 96
Table 3: Breast Cancer Therapeutics Market, Global, Pipeline Products, Preclinical, 2015 100
Table 4: Breast Cancer Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015 116
Table 5: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase I, 2015 117
Table 6: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase II, 2015 135
Table 7: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase III, 2015 148
Table 8: Breast Cancer Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015 152
Table 9: Breast Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021 152
Figure 1: Breast Cancer Therapeutics, Asia-Pacific, Age-Standardized Incidence per 100,000 population), 2012 12
Figure 2: Breast Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2001, 2006 and 2011 13
Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III, 2015 22
Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2015 23
Figure 5: Breast Cancer Therapeutics Market, Global, Heat Map 33
Figure 6: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products 40
Figure 7: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline 42
Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase (%), 2006-2015 43.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/breast-cancer-therapeutics-in-asia-pacific-markets-to-2021-growth-driven-by-increasing-uptake-of-premium-priced-biologics-and-rising-prevalence

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/